Characteristics and outcomes of patients with COVID-19 and liver injury: a retrospective analysis and a multicenter experience

被引:3
作者
Voiosu, Andrei [1 ,3 ]
Roman, Adina [4 ,5 ]
Pop, Ruxandra [1 ]
Boeriu, Alina [4 ,5 ]
Popp, Cristiana [2 ,3 ]
Zurac, Sabina [2 ,3 ]
Voiosu, Theodor [1 ,3 ]
Dobru, Daniela [4 ,5 ]
Mateescu, Bogdan [1 ,3 ]
机构
[1] Colentina Clin Hosp, Gastroenterol Dept, Bucharest, Romania
[2] Colentina Clin Hosp, Pathol Dept, Bucharest, Romania
[3] Carol Davila Univ Med & Pharm, Bucharest, Romania
[4] Mures Cty Clin Hosp, Gastroenterol Dept, 1 Gheorghe Marinescu St, Targu Mures, Romania
[5] Univ Med Pharm Sci & Technol George Emil Palade T, Targu Mures, Romania
关键词
COVID-19; liver injury; SARS-CoV-2; drug-induced liver injury; hepatitis; hydroxychloroquine; lopinavir/ritonavir; antiviral therapy;
D O I
10.2478/rjim-2021-0027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Patients with COVID-19 frequently present abnormal elevated liver function tests of unknown clinical significance. We aimed to investigate the characteristics and factors influencing outcome in patients with confirmed SARS-CoV-2 infection and liver injury on admission. Methods: This is a retrospective observational study of patients hospitalized in two COVID units in Romania. Relevant data on clinical and laboratory parameters and medication administered during the admission were analyzed to identify predictors of a negative outcome. Patients with confirmed COVID-19 and liver function tests (LFTs) above the upper limit of normal were included in the analysis. Results: From 1,207 patients, we identified 134 patients (11%) with abnormal LFTs during hospitalization. The majority of patients had mildly elevated levels and a predominantly cholestatic pattern of liver injury. Patients who received lopinavir/ritonavir were more likely to have increased ALAT levels (p<0.0001). Sixteen patients had pre-existing chronic liver disease, and they were more likely to suffer from severe COVID-19 (p=0.009) and have a negative outcome (p<0.001), but on multivariate analysis, only the severity of COVID-19 was predictive of death (OR 69.9; 95% CI 6.4-761.4). Conclusions: Mild liver injury is relatively common in COVID-19 and possibly influenced by medication. Patients with chronic liver disease are at high risk for negative outcome, but the severity of the infection is the only predictor of death.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 14 条
  • [1] Liver injury in COVID-19: The current evidence
    Alqahtani, Saleh A.
    Schattenberg, Joern M.
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (05) : 509 - 519
  • [2] Liver function recovery of COVID-19 patients after discharge, a follow-up study
    An, Ya-Wen
    Song, Shuo
    Li, Wei-Xin
    Chen, Yong-Xin
    Hu, Xiao-Peng
    Zhao, Jia
    Li, Zhi-Wen
    Jiang, Guang-Yu
    Wang, Cheng
    Wang, Jian-Chun
    Yuan, Bo
    Liu, Han-Qing
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (01): : 176 - 186
  • [3] EASL Clinical Practice Guidelines: Drug-induced liver injury
    Andrade, Raul J.
    Aithal, Guruprasad P.
    Bjornsson, Einar S.
    Kaplowitz, Neil
    Kullak-Ublick, Gerd A.
    Karlsen, Tom H.
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (06) : 1222 - 1261
  • [4] Liver injury in the era of COVID-19
    Cichoz-Lach, Halina
    Michalak, Agata
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (05) : 377 - 390
  • [5] The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection A Systematic Review and Meta-Analysis
    Dong, Zi-yuan
    Xiang, Bing-Jie
    Jiang, Min
    Sun, Ming-jun
    Dai, Cong
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (01) : 67 - 76
  • [6] Review article: COVID-19 and liver disease-what we know on 1st May 2020
    Garrido, Isabel
    Liberal, Rodrigo
    Macedo, Guilherme
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (02) : 267 - 275
  • [7] WGO Guidance for the Care of Patients With COVID-19 and Liver Disease
    Hamid, Saeed
    Alvares da Silva, Mario R.
    Burak, Kelly W.
    Chen, Tao
    Drenth, Joost P. H.
    Esmat, Gamal
    Gaspar, Rui
    LaBrecque, Douglas
    Lee, Alice
    Macedo, Guilherme
    McMahon, Brian
    Ning, Qin
    Reau, Nancy
    Sonderup, Mark
    van Leeuwen, Dirk J.
    Armstrong, David
    Yurdaydin, Cihan
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (01) : 1 - 11
  • [8] COVID-19 and the liver
    Jothimani, Dinesh
    Venugopal, Radhika
    Abedin, Mohammed Forhad
    Kaliamoorthy, Ilankumaran
    Rela, Mohamed
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 (05) : 1231 - 1240
  • [9] Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis
    Kunutsor, Setor K.
    Laukkanen, Jari A.
    [J]. JOURNAL OF INFECTION, 2021, 82 (01) : 186 - 190
  • [10] Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study
    Marjot, Thomas
    Moon, Andrew M.
    Cook, Jonathan A.
    Abd-Elsalam, Sherief
    Aloman, Costica
    Armstrong, Matthew J.
    Pose, Elisa
    Brenner, Erica J.
    Cargill, Tamsin
    Catana, Maria-Andreea
    Dhanasekaran, Renumathy
    Eshraghian, Ahad
    Garcia-Juarez, Ignacio
    Gill, Upkar S.
    Jones, Patricia D.
    Kennedy, James
    Marshall, Aileen
    Matthews, Charmaine
    Mells, George
    Mercer, Carolyn
    Perumalswami, Ponni, V
    Avitabile, Emma
    Qi, Xialong
    Su, Feng
    Ufere, Nneka N.
    Wong, Yu Jun
    Zheng, Ming-Hua
    Barnes, Eleanor
    Barritt, Alfred S.
    Webb, Gwilym J.
    [J]. JOURNAL OF HEPATOLOGY, 2021, 74 (03) : 567 - 577